15.10SEK-13.32%Mkt Cap: 845.57M SEKP/E: —Last update: 2026-06-01
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial fo…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap845.57M SEK
Enterprise Value867.64M SEK
Revenue (TTM)—
Gross Profit0 SEK
Net Income (TTM)-110.83M SEK
Revenue/Share—
Last Price15.10 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees8
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0008241491
Valuation
P/E (Trailing)—
P/E (Forward)-9.79
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B4.81
EPS (TTM)-49.66
EPS (Forward)-1.78
52W Range
12.8218% of range25.30
52W High25.30 SEK
52W Low12.82 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-65.08%
ROA-50.26%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-97.33M SEK
CapEx (TTM)—
FCF Margin—
FCF Yield-7.90%
Net Debt-64.71M SEK
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio5.74
Quick Ratio5.61
Book Value/Sh3.620 SEK
Cash/Share1.229 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)34.65 SEK
Target Range30.00 SEK – 39.30 SEK
# Analysts2
Ownership
Shares Out.56.00M
Float30.87M
Insiders29.87%
Institutions19.44%
Technical
SMA 5016.61 (-9.1%)
SMA 20019.79 (-23.7%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)372.41K
Avg Vol (10d)490.42K
Technical Indicators
RSI (14)60.5
MACD-0.3144
MACD Signal-0.6919
MACD Hist.+0.3776
BB Upper17.52 SEK
BB Middle15.03 SEK
BB Lower12.55 SEK
BB Width33.06%
ATR (14)1.094 SEK
Vol Ratio (20d)1.34x